Comparison of clinical characteristics of COVID-19 in pregnant women between the Delta and Omicron variants of concern predominant periods.
Comparison of clinical characteristics of COVID-19 in pregnant women between the Delta and Omicron variants of concern predominant periods.
复制标题
DOI：
10.1016/j.jiac.2022.09.005
复制
发表时间：
2023-01
影响因子：
2.2
通讯作者：
Ohmagari, Norio
中科院分区：
文献类型：
--
作者：
Shoji, Kensuke;Tsuzuki, Shinya;Akiyama, Takayuki;Matsunaga, Nobuaki;Asai, Yusuke;Suzuki, Setsuko;Iwamoto, Noriko;Funaki, Takanori;Yamada, Masaki;Ozawa, Nobuaki;Yamaguchi, Koushi;Miyairi, Isao;Ohmagari, Norio
关键词：
有关严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 变异毒株对孕妇 2019 年冠状病毒病 (COVID-19) 临床表现和结果影响的信息有限。使用日本全国 COVID-19 登记处的数据进行了一项回顾性观察研究。我们发现在研究期间住院的有症状的 COVID-19 孕妇。 Delta和Omicron关注变体（VOC）的主要时期分别定义为2021年8月1日至12月31日和2022年1月1日至5月31日。比较了 Delta 和 Omicron VOC 时期患者的临床特征。此外，还进行了逻辑回归分析，以确定发展为中度至重度 COVID-19 的风险因素。研究期间，发现了 310 名有症状的 COVID-19 孕妇病例；在 Delta 和 Omicron VOC 期间，分别有 111 名和 199 名患者住院。在 Omicron VOC 时期，流鼻涕和喉咙痛更为常见，而疲劳、味觉障碍和嗅觉功能障碍则较少见。在多变量 Logistic 回归分析中，妊娠后期发病（OR：2.08 [1.24–3.71]）和 Delta VOC 期间发病（OR：2.25 [1.08–4.90]）与中度至重度 COVID-19 独立相关，而两剂 SARS-CoV-2 疫苗可预防中度至重度 COVID-19 的发展（OR： 0.34 [0.13–0.84]）。 Delta 和 Omicron VOC 时期孕妇的 COVID-19 临床表现有所不同。在整个 Delta 和 Omicron VOC 时期，SARS-CoV-2 疫苗接种仍然可以有效预防严重的 COVID-19。
Information regarding effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant strains on clinical manifestations and outcomes of coronavirus disease 2019 (COVID-19) in pregnant women is limited. A retrospective observational study was conducted using the data from the nationwide COVID-19 registry in Japan. We identified pregnant patients with symptomatic COVID-19 hospitalized during the study period. The Delta and Omicron variants of concern (VOC) predominant periods were defined as August 1 to December 31, 2021 and January 1 to May 31, 2022, respectively. Clinical characteristics were compared between the patients in the Delta and Omicron VOC periods. In addition, logistic regression analysis was performed to identify risk factors for developing moderate-to-severe COVID-19. During the study period, 310 symptomatic COVID-19 cases of pregnant women were identified; 111 and 199 patients were hospitalized during the Delta and Omicron VOC periods, respectively. Runny nose and sore throat were more common, and fatigue, dysgeusia, and olfactory dysfunction were less common manifestations observed in the Omicron VOC period. In the multivariable logistic regression analysis, onset during the later stage of pregnancy (OR: 2.08 [1.24–3.71]) and onset during the Delta VOC period (OR: 2.25 [1.08–4.90]) were independently associated with moderate-to-severe COVID-19, whereas two doses of SARS-CoV-2 vaccine were protective against developing moderate-to-severe COVID-19 (OR: 0.34 [0.13–0.84]). Clinical manifestations of COVID-19 in pregnant women differed between the Delta and Omicron VOC periods. SARS-CoV-2 vaccination was still effective in preventing severe COVID-19 throughout the Delta and Omicron VOC periods.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1503/cmaj.211248
发表时间：
2021-10-25
期刊：
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
影响因子：
--
作者：
Fisman DN;Tuite AR
通讯作者：
Tuite AR
DOI：
10.1016/s0140-6736(22)00327-0
发表时间：
2022-04-23
期刊：
Lancet (London, England)
影响因子：
--
作者：
Menni C;Valdes AM;Polidori L;Antonelli M;Penamakuri S;Nogal A;Louca P;May A;Figueiredo JC;Hu C;Molteni E;Canas L;Österdahl MF;Modat M;Sudre CH;Fox B;Hammers A;Wolf J;Capdevila J;Chan AT;David SP;Steves CJ;Ourselin S;Spector TD
通讯作者：
Spector TD
影响因子：
82.9
作者：
Stock SJ;Carruthers J;Calvert C;Denny C;Donaghy J;Goulding A;Hopcroft LEM;Hopkins L;McLaughlin T;Pan J;Shi T;Taylor B;Agrawal U;Auyeung B;Katikireddi SV;McCowan C;Murray J;Simpson CR;Robertson C;Vasileiou E;Sheikh A;Wood R
通讯作者：
Wood R
接种 BNT162b2 疫苗与孕妇 SARS-CoV-2 感染率之间的关系
影响因子：
120.7
作者：
Goldshtein, Inbal;Nevo, Daniel;Segal, Yaakov
通讯作者：
Segal, Yaakov